
| 10.1097/PRS.0000000000002682
http://scihub22266oqcxt.onion/10.1097/PRS.0000000000002682
 C4998971!4998971!27556760
free
free
free
Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=27556760&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
|  
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\27556760.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117
Plast+Reconstr+Surg 2016 ; 138 (3): 18S-28S Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
|
Biology and Biomarkers for Wound Healing #MMPMID27556760Lindley LE; Stojadinovic O; Pastar I; Tomic-Canic MPlast Reconstr Surg 2016[Sep]; 138 (3): 18S-28S PMID27556760show ga
Background: As the population grows older, the incidence and prevalence of conditions which lead to a predisposition for poor wound healing also increases. Ultimately, this increase in non-healing wounds has led to significant morbidity and mortality with subsequent huge economic ramifications. Therefore, understanding specific molecular mechanisms underlying aberrant wound healing is of great importance. It has, and will continue to be the leading pathway to the discovery of therapeutic targets as well as diagnostic molecular biomarkers. Biomarkers may help identify and stratify subsets of non-healing patients for whom biomarker-guided approaches may aid in healing. Methods: A series of literature searches were performed using Medline, PubMed, Cochrane Library, and Internet searches. Results: Currently, biomarkers are being identified using biomaterials sourced locally, from human wounds and/or systemically using systematic high-throughput ?omics? modalities (genomic, proteomic, lipidomic, metabolomic analysis). In this review we highlight the current status of clinically applicable biomarkers and propose multiple steps in validation and implementation spectrum including those measured in tissue specimens e.g. ?-catenin and c-myc, wound fluid e.g. MMP?s and interleukins, swabs e.g. wound microbiota and serum e.g. procalcitonin and MMP?s. Conclusions: Identification of numerous potential biomarkers utilizing different avenues of sample collection and molecular approaches is currently underway. A focus on simplicity, and consistent implementation of these biomarkers as well as an emphasis on efficacious follow-up therapeutics is necessary for transition of this technology to clinically feasible point-of-care applications.�
  
DeepDyve Pubget Overpricing | 
|